Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-11T02:34:27.737Z Has data issue: false hasContentIssue false
  • English
  • Français

Nuevos anticonvulsivantes en la profilaxis del trastorno bipolar

Published online by Cambridge University Press:  12 May 2020

José Luis López de Heredia
José Luis López de Heredia*
Affiliation:
Hospital de Santiago, Vitoria
Get access

Extract

En términos generales podríamos considerar que la sustancia estabilizante más eficaz en el tratamiento del trastomo bipolar debería cumplir las siguientes características: buena tolerancia, pocos efectos secundarios, rapidez de acción, que mejore un polo sin empeorar el otro, que sea eficaz en el tratamiento de ambos polos y que prevenga las recaídas.

El litio, la sustancia clásica y que algunos podrían considerar la más específica para el tratamiento del trastomo bipolar, cumple algunos criterios pero no todos los criterios “ideales”.

Type
Sección Española
Information
European Psychiatry (Ed. Española) , Volume 10 , Issue 8 , November 2003 , pp. 537 - 542
Copyright
Copyright © European Psychiatric Association 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Ballenger, JC.The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49(suppl 9):915–921.Google ScholarPubMed
Ballenger, JC, Post, RM.Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 1980; 137: 782–790.Google ScholarPubMed
Bauer, MS, Whybrow, PC, Winokor, A.Rapid cycling bipolar affective disorder. Arch Gen Psychiatry 1990; 47: 427–432.CrossRefGoogle ScholarPubMed
Bowden, CL, Calabrese, JR, et al. Efficacy of lamotrigine in bipolar disorders: overwiew of double-blind, placebo-controlled studies (Abstract). Presented at the 37th annual meeting of the American College of Neuropychopharmacology. Dec 10- 2000; San Juan, Puerto Rico.Google Scholar
Bowden, CL.Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56(suppl 3): 25–30.Google ScholarPubMed
Bowden, CL, Brugger, AM, Swann, AC, Calabrese, JR, Janicak, PG, Petty, F, et al.Efficacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 1994; 271: 918–924.CrossRefGoogle Scholar
Brady, KT, Sonne, SC, Antón, R, Ballenger, JC.Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995; 56: 1181–21.Google ScholarPubMed
Bryant, AE, Dreifuss, FE.Valproic acid hepatic fatalities: III. US experience since 1986. Neurology 1996; 46: 465–469.Google ScholarPubMed
Buzan, RD, Dubovsky, SL.Recurrence of lamotrigine-associated rash with rechallenge. J Clin Psychiatry 1998;59: 87.Google ScholarPubMed
Cabrera, JF, Muehlbauer, HD, Schley, J, et al.Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry 1986; 19: 282–283.CrossRefGoogle Scholar
Calabrese, JR.Delucchi GA. Spectrum of afficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431–434.Google Scholar
Calabrese, JR, Fatemi, SH, Woyshville, MJ.Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996;153:123.Google ScholarPubMed
Calabrese, JR, Shelton, S, Keck, PE, et al. Topiramate in severe treatment refractory mania. New Research and Program Abstraes, American Psychiatric Association Annual Meeting, Toronto, Cañada, May 30-June 4, Pages 121-122.Google Scholar
Calabrese, JR, Keck, PE Jr, McElroy, SL, et al.A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Pschopharmacol 2001;21:340.CrossRefGoogle ScholarPubMed
Calabrese, JR.Topiramate versus placebo in mania. Presented at the 153nd annual meeting of the American Psychiatry Association. Chicago. May 13-18, 2000.Google Scholar
Calabrese, JR, Fatemi, SH, Kuyawa, M, Woyshville, MJ.Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16(suppl 1): 24–31.CrossRefGoogle ScholarPubMed
Calabrese, JR, Bowden, CL, Sachs, GS, Ascher, JA, Monaghan, E, Rudd, GD.A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79–88.CrossRefGoogle ScholarPubMed
Calabrese, JR, Suppes, T, Bowden, CL, et al.Lamictal 614 Study Group. A double-blind placebo-controlled prophylaxis study of lamotrigine in rapid-cicling bipolar disorder. J Clin Psychiatry 2000; 61: 841–850.Google ScholarPubMed
Chengappa, KNR, Rathore, D, Levine, J, Atzer, R, Solai, L, Parepally, H, et al.Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders 1999; 1: 42–53.CrossRefGoogle ScholarPubMed
Cowdry, RW, Wehr, TA, Zis, AP, Goodwin, FK.Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry 1983; 40: 414–420.CrossRefGoogle ScholarPubMed
Crawford, P.An audit of topiramate use in a general neurology clinic. Seizure 1998; 7: 207–11.CrossRefGoogle Scholar
Dardennes, R, Even, DC, Bange, F, Heim, A.Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder. Br J Psychiatry 1995; 166: 378–381.CrossRefGoogle Scholar
Denicoff, KD, Smith-Jackson, EE, Bryan, AL, Ali, SO, Post, RM.Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1998; 154: 1456–1458.Google Scholar
Emrich, HM, Dose, M, Von, Zerssen D.Action of sodium-valproate and oxcarba-zepine in patients with affective disorders. In:Emrrich, HM, Okuma, T, Mueller, AA(Eds) Anticonvulsivants in affective disorders.Int Congr Series No 626. Excerpta Medica; Amsterdam, 1984; pp. 45-55.Google Scholar
Fatemi, SH, Rapport, DJ, Calabrese, JR, Thuras, P.Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58: 522–527.CrossRefGoogle ScholarPubMed
Fenn, HH, Robinson, D, Luby, V, Dangel, C, Buxton, E, Beattie, M, et al.Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: A 5-year naturalistic study. Am J Psychiatry 1996; 153: 711–713.Google ScholarPubMed
Freeman, TW, Clothier, JL, Pazzaglia, P, Lesem, MD, Swann, AC.A double-blind comparison of valproate and lithium in the treatment of acute manía. Am J Psychiatry 1992; 149: 108–111.Google ScholarPubMed
Frye, MA, et al.A placebo contrlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychofarmacolol 2000; 20: 607–614.CrossRefGoogle ScholarPubMed
Gilman, JT.Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995; 29: 144–151.CrossRefGoogle ScholarPubMed
Gordon, A, Price, LH.Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999; 156: 968–9.CrossRefGoogle ScholarPubMed
Greil, W, Kruegerl, G, et al.Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: an open clinical trial, In: Pichot, P, et al (Eds) Psychiatry The State of the art. Vol 3: Pharmacopsychiatry. Proc VII World Congr. Psychiatry, July 11-16, 1983, Vienna, Austria. PlenumPress; New York, 1985; pp. 491-494.Google Scholar
Kaufman, KR, Gerner, R.Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163–165.CrossRefGoogle Scholar
Keck, PE Jr, McElroy, SE, Bennet, JA.Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry 1996; 57(supl 13): 13–18.Google ScholarPubMed
Keck, PE Jr, McElroy, SL, Strakowski, SM, Stanton, SP, Kizer, DL, Balistreri, TM, et al.Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996; 57: 292–297.Google ScholarPubMed
Kramlinger, KG, Post, RM.Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am J Psychiatry 1990; 147: 615–620.Google ScholarPubMed
Kusumakar, V, Yatham, LN.Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry 1997;154: 1171–1172.Google ScholarPubMed
Labbate, LA, Rubey, RN.Lamotrigine for treatment-refractory bipolar disorder. Am J Psychiatry 1997;154:1317.Google ScholarPubMed
Lambert, PA, Carraz, G, Borselli, S, Carrel, S.Action neuropsychotrope d'un nou-vel antiépileptique: le Dépamide. Ann Méd Psychol (Paris) 1996; 1: 707–710.Google Scholar
Marcotte, D.Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disor 1998; 50: 245–251.CrossRefGoogle ScholarPubMed
McElroy, SL, Keck, PE Jr, Pope, HG Jr.Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16–24.Google ScholarPubMed
McElroy, SL, Keck, PE Jr, Pope, HG Jr, Hudson, JI.Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12(suppl l):42–52.CrossRefGoogle ScholarPubMed
McElroy, SL, Keck, PE, Stanton, SP, Tugrul, KC, Bennet, JA, Strakowski, SM.A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57: 142–146.Google ScholarPubMed
McElroy, SL, Soutullo, CA, Keck, PE Jr, Ketz, GF.A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9: 99–103.CrossRefGoogle ScholarPubMed
McElroy, SL, Kmetz, GF, Keck, Jr PE.A pilot trial of adjuntive topiramate in the treatment of bipolar disorder. Póster presented at the XXIst Congress of the Collegium internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland JulyGoogle Scholar
Mclntyre, RS; Mancini, D, McCann, S, et al.Topiramate vs Bupropion SR added to mood stabilizer therapy for depressive phase of bipolar disorder: a single-blind study. Presented at Neuropsychopharmacology Congress; July 6-19, Rhodes, Greece.Google Scholar
Mordecai, DJ, Sheikh, JI, Click, ID.Divalproex for the treatment of geriatric bipolar disorder. Int J Geriatr Psychiatry 1999; 14: 494–496.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
Mueller, AA, Stoll, KD.Carbamazepine and Oxcarbazepine in the treatment of manic syndromes- studies in Germany. In: Emrich, HM, Okuma, T, Muller, AA (Eds) Anticonvulsivants in affective disorders. Int Conr series No 626. Excerpta Medica, Amsterdam, 1984; pp.139–147.Google Scholar
Nemeroff, CB.Augmentation regimens for depression. J Clin Psychiatry 1991; 52(suppl):21–27.Google ScholarPubMed
Okuma, T, Yamashita, I, Takahashi, R, Itoh, H, Otsuki, S, Watanabe, S, et al.Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23: 143–150.CrossRefGoogle ScholarPubMed
Pande, A, et al.Gabapentine in bipolar disorders: a placebo controlled trial of adjuntive therapie. Bipolar Disorders 2000; 2: 249–255.CrossRefGoogle Scholar
Pazzaglia, PJ, Post, RM, Ketter, TA, Callahan, AM, Marangell, LB, Frye, MA, et al.Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychoparmacol 1998; 18: 404–413.CrossRefGoogle ScholarPubMed
Pellock, JM.The clinical efficacy of lamotrigine as an anti- epileptic drug. Neurology 1994; 44 (Suppl 11): 29–35.Google Scholar
Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT.Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21: 71–83.CrossRefGoogle ScholarPubMed
Post, RM, Ketter, TA, Denikoff, K, Pazzaglia, PJ, Leverich, GS, Marangell, LB, et al.The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 1996; 128: 115–129.CrossRefGoogle ScholarPubMed
Post, RM, Denikoff, KD, Frye, MA, Leverich, GS.Re-evaluating the carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 1997; 170: 202–204.CrossRefGoogle Scholar
Post, RM, Kramlinger, KG, Joffe, RT, Roy-Byrne, PP, Rosoff, A, Frye, MA, et al.Rapid cycling bipolar affective disorder: lack of relation to hipothyroidism. Psychiatry Res 1997; 72:1–7.CrossRefGoogle Scholar
Prien, RF, Gelenberg, AJ.Alternative to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989; 146: 840–848.Google ScholarPubMed
Richens, A.Safety of lamotrigine. Epilepsia 1994; 35 (Suppl 5):37–40.CrossRefGoogle ScholarPubMed
Rush, PF, Davis, JM, Calabrese, JR, Kimmel, SE, Kramer, GL, Small, JG, et al.Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 1996; 39: 278–284.Google Scholar
Sachs, GS.Bipolar mood disorder: practical strategies for acute an maint nance phase treatment. J Clin Psychopharmacol 1996; 16(suppl l):32–47.CrossRefGoogle Scholar
Schaffer, CB, Schaffer, LC.Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997; 154: 291–292.Google ScholarPubMed
Shorvon, SD.Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37(suppl 2):18–22.CrossRefGoogle ScholarPubMed
Small, JG, Klapper, MH, Milstein, V, Kellams, JJ, Miller, MJ, Marhenke, JD, et al.Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915–921.CrossRefGoogle ScholarPubMed
Spina, E, Pisani, F, Perucca, E.Clinically significant pharmacokinetic drug interactions with carbamazepine: An update. Clin Pharmacokinet 1996; 31: 198–214.CrossRefGoogle ScholarPubMed
Sporn, J, Sachs, G.The anticonvulsivant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185–189.CrossRefGoogle Scholar
Stuppaeck, CH, Barnas, C, Schwitzer, J, Fleischhacker, WW.Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. J Clin Psychiatry 1994; 55: 146–150.Google ScholarPubMed
Suppes, T, Brown, ES, McElroy, SL, Keck, PE Jr, Nolen, W, Kupka, R, et al.Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95–98.CrossRefGoogle ScholarPubMed
Swann, AC, Bowden, CL, Morris, D, Calabrese, JR, Petty, F, Small, J, et al.Depression During Mania. Treatment Response to Lithium or Divalproex. Arch Gen Psychiatry 1997; 54: 37–42.CrossRefGoogle ScholarPubMed
Takekazi, H, Hanaoka, M.The use of carbamazepine (tegretol) in the control of maniac-depressive states. Clin Psychiatr 1971; 13: 173–183.Google Scholar
Tohen, M, Castillo, J, Pope, HG, Herbstein, J.Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacology 1994; 14: 67–70.CrossRefGoogle ScholarPubMed
Velikonja, M, Heinrich, K.Effect of oxcarbazepine (CG 47.680) on affective and schizoaffective symptoms a preliminary repot. In: Emrich, HM, Okuma, T, Mueller, AA (Eds) Anticonvulsivants in affective disorders. Int Congr Series No 626. Excerpta Medica; Amsterdam, 1984; pp. 208–210.Google Scholar
Vieta, E, Colom, F, Martmez-Arán, A, Benabarre, A, Gastó, C.Los nuevos antiepi-lépticos en el tratamiento de los trastornos afectivos. Psicofarmacología 1998; 2: 7–14.Google Scholar
Vieta, E, Martínez, Aran A, Nieto, E, Reinares, M, Benabarre, A, Gastó, C.Adjuntive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000; 15: 433–7.CrossRefGoogle Scholar
West, SA, McElroy, SL, Keck, PE.Valproato. In: Goodnick, PJ (ed). Predictores de la respuesta al tratamiento en los trastornos del estado de ánimo. Barcelona: Edi-ka Med 1997:121–132.Google Scholar